NCT01041040View on ClinicalTrials.gov

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

PHASE4CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

January 31, 2013

Conditions

Acute Myeloblastic Leukemia

Interventions

DRUG

gemtuzumab

gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)

Trial Locations (1)

Unknown

Hoapital La Fe, Valencia

All Listed Sponsors

lead

PETHEMA Foundation

OTHER

NCT01041040 - LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter